What AiVF does

AIVF Ltd. is an Israeli medical technology company founded in 2018 by clinical embryologist Daniella Gilboa (CEO) and reproductive medicine specialist Prof. Daniel Seidman (CMO), headquartered in Tel Aviv. The company develops an AI-powered platform for in vitro fertilization (IVF), centered on the EMA (Embryology Management Assistant) system, which applies deep learning and computer vision to time-lapse embryo images to predict clinical pregnancy probability and assist embryologists in embryo selection. The platform is modular, including AIVF Day-3 (early-stage evaluation), AIVF Day-5 (blastocyst evaluation), AIVF Genetics (non-invasive probabilistic euploidy scoring that substitutes for invasive PGT-A biopsy), Advanced IVF Analytics (EMR-connected KPI and data mining tools), and an Integrated Messaging Dashboard for care team coordination. AIVF also operates the ART Compass subsidiary for IVF lab management, and offers a patient-facing mobile app.

The company sells to enterprise IVF clinics and fertility centers via direct field sales on an annual subscription basis, with deployments integrated into existing clinic workflows through connectors to time-lapse incubators (Embryoscope, Geri via Genea Biomedx) and EMR systems. It holds CE Mark, ISO 13485, ISO 27001, ISO 27799, and is HIPAA and GDPR compliant; in the US, the AI is currently limited to investigational use pending FDA clearance. As of 2023, AIVF had raised approximately $35 million in total funding, including a $25 million Series A led by Insight Partners in June 2022, and operates across Israel, the United States, the United Kingdom, France, Ireland, Greece, and Brazil with reference customers including Perfetto Clinic, First IVF, Embryolab, and the American Hospital of Paris.

Name

AiVF

Legal name

AIVF Ltd.

Website

https://aivf.co

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

AIVF Ltd. is an Israeli medical technology company founded in 2018 that builds an AI-powered IVF platform (EMA) using deep learning on time-lapse embryo images to predict pregnancy probability and assist embryo selection, sold via enterprise SaaS subscriptions to IVF clinics and fertility centers globally.

Ownership category

akta.pro rank

Product category

Clinical decision-support software for IVF / reproductive medicine

NAICS

Software Publishers (5132), Custom Computer Programming Services (541511), Computer Systems Design Services (541512)

SIC

Services-Prepackaged Software (7372), Services-Computer Programming Services (7371), Services-Computer Integrated Systems Design (7373)

akta.pro primary industry

AI/ML Engineering & Model Development Services (BPAEAHAF)

Keywords

• AI embryo evaluation
• IVF clinical software
• Fertility clinic analytics
• Embryology management platform
• Reproductive medicine AI

Headquarters

HQ city

Tel Aviv

HQ country

Israel

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Others

Revenue model

1. SaaS Platform Subscription: AiVF operates on a B2B SaaS model providing IVF clinics with access to its AI-powered EMA platform. Clinics pay subscription fees for embryo evaluation, analytics, and communication tools.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels7 records

Core offering

AIVF develops and sells the EMA (Embryology Management Assistant) platform — an AI-powered clinical decision-support SaaS for IVF clinics that performs automated, deep-learning-based embryo evaluation (Day-3 and Day-5), non-invasive euploidy prediction via AIVF Genetics, and clinic-wide analytics and messaging, integrating with time-lapse incubators (Embryoscope, Geri) and EMR systems. The company also offers ART Compass (lab management) and a patient mobile app as adjacent products to its core IVF clinic software.

Product overview

AIVF offers a modular AI-powered IVF platform centered on the EMA (Embryology Management Assistant) system with interconnected modules for embryo evaluation, genetics analysis, analytics, and communication. The core EMA Platform provides Day-3 and Day-5 AI embryo evaluation powered by computer vision and predictive analytics. AIVF Genetics module adds non-invasive euploidy screening. The platform includes Advanced IVF Analytics for clinic data insights and an Integrated Messaging Dashboard for care team coordination. AIVF also provides a patient-facing Mobile App and operates ART Compass subsidiary for lab management. All modules share data through EMR connectivity for a unified clinic workflow.

Differentiator

Problem solved

Functional benefit

Brands

• AIVF Day-3: Early-stage embryo evaluation for clinical pregnancy prediction
• AIVF Day-5
• AIVF Genetics
• ART Compass
• FertilityOS

Products and services

• EMA Platform (Embryology Management Assistant) End-to-end AI-powered embryo evaluation SaaS platform that connects the entire IVF care team through automated embryo grading, analytics, and communication tools, integrating with time-lapse incubators (Embryoscope, Geri) and EMR systems. Designed for IVF clinics and fertility centers seeking to standardize embryo selection, reduce evaluation time, and improve pregnancy rates.
• AIVF Genetics Non-invasive AI tool that provides probabilistic euploidy estimates (0-99 score) for embryos using time-lapse imaging, integrating maternal age, embryo morphology scores, morphokinetic parameters, and Embryo Resilience data to support genetic-quality assessment without invasive PGT-A biopsy. Targeted at IVF clinics and reproductive medicine labs.
• ART Compass Wholly-owned AIVF subsidiary product offering IVF lab management tools and a clinic operating system for quality assurance and laboratory workflow support, used by fertility clinics and embryology labs.
• AIVF Mobile App Patient-facing mobile application that provides access to personal fertility health data processed by the clinic, remote journey monitoring, and scheduling features for patients undergoing IVF treatment.

Quantifiable outcome

• 70% probability of success for embryos with high AIVF score
• +4 more outcomes

Named customers4 records

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability7 records

Feature9 records

Partnerships

Two partnerships are on record, tiered flagship and core.

• American Hospital of ParisflagshipStrategic or Co-development Partner · 8 December 2025The American Hospital of Paris uses AIVF technology to analyze embryo development data, aiming to halve the number of IVF cycles needed to achieve pregnancy with 70% probability that recommended embryos will not have genetic abnormalities.
• Genea BiomedxcoreTechnology or Integration · 18 May 2023Strategic partnership announced in May 2023 to integrate AIVF's AI-powered EMA platform with Genea Biomedx's Geri time-lapse incubator, expanding support for AI-powered embryo evaluation.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Genea Biomedx: Genea Biomedx manufactures Geri time-lapse incubators and is AIVF's integration partner; as a major incubator OEM with R&D resources it represents both a channel and a potential competitor.
• Vitrolife: Vitrolife is a global IVF media, device and genomics supplier whose Embryoscope time-lapse incubator platform is integrated with AIVF; as a broad incumbent it could build or bundle competing AI embryo scoring.
• CooperSurgical: CooperSurgical is a large incumbent in fertility and reproductive medicine spanning devices, genomics (PGT-A) and lab services, with overlapping AI-adjacent capabilities and the distribution to challenge AIVF in clinics.
• FUJIFILM Irvine Scientific: FUJIFILM Irvine Scientific is a leading supplier of IVF media, devices and digital tools to fertility clinics, representing a broad incumbent whose scale and customer relationships compete with AIVF's clinic OS.
• Hamilton Thorne: Hamilton Thorne provides ART/IVF instruments and clinical devices globally; its installed base of laser systems and imaging hardware gives it a platform adjacent to AIVF's AI evaluation layer.

Direct peers

• Alife Health: Alife Health applies AI to IVF clinical decision support and embryo selection, directly competing with AIVF's EMA platform for the same fertility clinic customers with similar AI-on-time-lapse-imaging workflows.
• Fairtility: Fairtility offers AI-based embryo assessment and decision-support tools for IVF clinics, competing head-to-head with AIVF in automating embryo grading and ranking using time-lapse incubator data.
• Univfy: Univfy provides AI-based IVF success prediction and patient counseling tools to fertility clinics, directly competing with AIVF's analytics and decision-support positioning.

Emerging players

• Embryonics: Embryonics develops AI-powered embryo viability prediction for IVF, an emerging niche player overlapping with AIVF's Day-3/Day-5 evaluation offerings.

Others

• Progyny: Progyny is a leading fertility benefits management platform that influences which clinics and tools patients use; it is an adjacent ecosystem player whose provider selection decisions can drive or constrain AIVF clinic adoption.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xtwitter.com/AiVFtech
• Facebookfacebook.com/aivfaivf
• LinkedInlinkedin.com/company/aivf
• Instagraminstagram.com/aivf.aivf

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries2 records

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AiVF